Thermo Fisher Scientific Inc. has introduced CorEvidence, a proprietary cloud-based data lake platform aimed at optimizing pharmacovigilance case processing and safety data management procedures. This innovative platform complements Thermo Fisher's PPD clinical research business and enhances the capabilities of the existing CorEvitas clinical research registries.
The initial application of CorEvidence focuses on elevating pharmacovigilance workflow and deliverable management. Engineered to handle multiple data sources, the platform streamlines the coding, classification, and reporting of adverse events and safety events of interest for committed post-authorization safety studies. CorEvidence provides comprehensive support for pharmacovigilance deliverables, ensuring efficient, traceable, auditable, scalable, and compliant safety management for customer safety commitments, utilizing data collected through CorEvitas syndicated registries.
Thermo Fisher's acquisition of CorEvitas, a leading provider of gold-standard real-world evidence solutions, in August 2023, has significantly contributed to the development of this platform. CorEvitas offers a range of services, including 12 registries, featuring nine autoimmune and inflammatory syndicated registries. Their data intelligence platform facilitates the creation and expansion of clinical registries across various therapeutic areas, amassing structured patient clinical data from over 400 investigator sites and more than 100,000 patients followed longitudinally. Leveraging the CorEvitas model, the platform is actively addressing regulatory requirements for over 15 long-term post-authorization safety studies spanning eight disease indications.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!